Abstract:Background: For advanced non-small cell lung cancer (NSCLC) patients, first-line chemotherapy is the main treatment in the clinic despite its efficacy is limited and adverse effects are always inescapable. Ginsenoside Rg3, an anti-cancer active ingredient by suppressing angiogenesis, has been increasingly widely used as an adjuvant in first-line chemotherapy for advanced NSCLC to optimize treatment in China. However, no comprehensive meta-analyses have been conducted to estimate the efficacy and safety of the therapy combining ginsenoside Rg3 and first-line chemotherapy in advanced NSCLC patients. Methods: Randomized controlled trails using a combination of first-line chemotherapy and ginsenoside Rg3 for advanced NSCLC patients were searched and selected from six databases. The Cochrane Risk of Bias tool was used to assessed the quality of these selected original researches. And we used Review Manager 5.3 and STATA to analyze the data. Results: Twenty-two RCTs that matched our selection criteria with a number of 2202 patients were included in our review. The results showed that compared with first-line chemotherapy alone, the combination of ginsenoside Rg3 and first-line chemotherapy could better improve the objective response rate (ORR) (RR [95% CI], 1.44 [1.27, 1.63], p < 0.00001 ), the disease control rate (DCR) (RR [95% CI], 1.24 [1.12, 1.38], p < 0.0001), karnofsky performance status (KPS) (RR [95% CI], 1.62 [1.42, 1.84], p < 0.00001), one-year survival rate (RR [95% CI], 1.49 [1.08, 2.06], p = 0.01), two-year survival rate (RR [95% CI], 6.22 [1.68, 22.95], p = 0.006), weight change (RR [95% CI], 1.31 [1.04, 1.66], p = 0.02), and higher reduce the VEGF levels (RR [95% CI], -2.21 [-4.03, -0.38], p = 0.02), the incidence of gastrointestinal reactions (RR [95% CI], 0.66 [0.47, 0.93], p = 0.02) and bone marrow suppression (RR [95% CI], 0.43 [0.30, 0.61], p < 0.00001). Conclusion: Ginsenoside Rg3 can enhance drug efficacy and reduce drug-induced toxicity from chemotherapy. These findings provide helpful information for clinicians indicating that a therapy combined of ginsenoside Rg3 and first-line chemotherapy may be used to optimal the treatment of advanced NSCLC.

[Effect of Ginsenoside Rh2 on Immunocompetence of Alveolar Macrophages in Patients with Non-Small Cell Lung Cancer].

Study of immunocompetence of alveolar macrophages in patients with non small cell lung cancer cultivated with gemzar

Therapeutic effects of ginsenoside Rh2 on multi-drug resistant leukemia cell line K562 /VCR

Effect of Rg3 on the expression of CD 80/86 and cellular immune function in patients with nasopharyngeal carcinoma after radiotherapy

The effect of Rg3 ginsenosides on cellular immune function of nasopharyngeal carcinoma patients with radiotherapy

Ginsenoside Rh2 Attenuates Allergic Airway Inflammation By Modulating Nuclear Factor-Kappa B Activation In A Murine Model Of Asthma

Effects of G-Rh2 on mast cell-mediated anaphylaxis via AKT-Nrf2/NF-κB and MAPK-Nrf2/NF-κB pathways

Effect of Sulfated 20(S)-ginsenoside Rh2 on Function of Chicken Immunocompetent Cells in Vitro

Synergistic Effect of Ginsenoside Rh2 Combines with Ionizing Radiation on CT26/ luc Colon Carcinoma Cells and Tumor-Bearing Animal Model

The immunomodulatory effects of ginsenoside derivative Rh2-O on splenic lymphocytes in H22 tumor-bearing mice is partially mediated by TLR4

The Efficacy of Ginsenoside Rg3 Combined with First-line Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer in China: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

[The Effect of 20(R)-Ginsenoside Rg3 on the Differential Expression of Cell Signaling Genes and Other Related Genes in Human Lung Adenocarcinoma Cell Line A549].

[Study on apoptosis of human lung adenocarcinoma cell line A549/DDP induced by ginsenoside Rh₂ in vitro].

[Effect of compound Rhizoma Smilacinus granules on the expression of Bcl-2 and Bax gene in A549 cell lines of non-small cell lung cancers].

EFFECTS OF GINSENOSIDE Rg1 AND ITS METABOLITE Rh1 ON THE FUNCTION OF IMMUNOCYTE IN MICE

Observation of Curative Effect of Combined 20(R) - Ginsenoside Rg3 with chemotherapy on nonsmall- cell Lung Cancers

Ginsenoside Rh(2) enhances antitumour activity and decreases genotoxic effect of cyclophosphamide

Ginsenosides Rh2 and Rg3 exert their anti-cancer effects on non-small cell lung cancer by regulating cell autophagy and choline-phosphatidylcholine metabolism

Antitumor and Immunomodulatory Effects of Ginsenoside Rh2 and Its Octyl Ester Derivative in H22 Tumor-Bearing Mice

Effect and Mechanism of Ginsenoside Rg3 on Postoperative Life Span of Patients with Non-Small Cell Lung Cancer

[Research on the Mechanism of Ginsenoside Rh2 Reversing the Resistance of Lung Adenocarcinoma Cells to Cisplatin].